Current and future issue of molecular target therapy in hematological malignancy

Review Article: Molecular Target Treatment Targeted Therapy in Breast Cancer: Current Status and Future Directions

Targeted drugs against breast cancer are being developed centering around ones targeting HER2. In addition to trastuzumab and lapatinib that were already approved in Japan, promising drugs are being developed one after another. Basic mechanisms of their action and resistance emergence are being clarified step by step. In consideration of extraordinarily high medical expenditures of targeted dru...

Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer related mortality worldwide. The incidence of HCC has been increasing annually. Viral infection, alcohol usage, and other causes of cirrhosis have been identified as major risk factors for HCC development. The underlying pathogenesis has not been as well defined. There have been multiple hypotheses to the specific mechani...

molecular and physiological characterizations of floral scent production in rosa damascena mill.

گل محمدی (r. damascena mill.)مهمترین گونه ای است که در تولید گلاب، عطر و اسانس، در صنعت عطرسازی و دارویی کاربرد دارد. با وجود اهمیت عطر گل محمدی، پژوهش های مولکولی و بیوشیمیایی عطر گل این گونه هنوز در مراحل ابتدایی است. در این پژوهش، ویژگی های مولکولی و فیزیولوژیکی تولید عطر در گل محمدی در آزمایش های مختلف مورد بررسی قرار گرفتند. در آزمایش اول، پژوهشی به منظور بررسی تنوع شیمیایی اسانس میان 44 ت...

Current issue and future submissions, contextualized

Multidrug resistance in hematological malignancy.

The recent treatment of hematological malignancies appears to be unsatisfactory in child and adult patients with acute myeloid leukemia and adult patients with acute lymphocytic leukemia. A major problem in the treatment of leukemia is caused by the development of drug resistance to chemotherapeutic agents, which is already present at diagnosis or after chemotherapy as a minimal residual diseas...